|3Jun 20, 7:31 PM ET

Palmetto Partners, Ltd. 3

3 · XERIS PHARMACEUTICALS INC · Filed Jun 20, 2018

Insider Transaction Report

Form 3
Period: 2018-06-20
Holdings
  • Series A Preferred Stock

    Common Stock (930,383 underlying)
  • Stock Option (right to buy)

    Exercise: $1.98Exp: 2025-02-25Common Stock (11,228 underlying)
  • Series B Preferred Stock

    Common Stock (581,992 underlying)
  • Series B Preferred Stock

    Common Stock (447,686 underlying)
Footnotes (5)
  • [F1]The securities are owned by Palmetto Partners 2014, LP, who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2015, LP.
  • [F2]The securities are owned by Palmetto Partners 2015, LP., who is a member of a group with Palmetto Partners, Ltd. and Palmetto Partners 2014, LP.
  • [F3]The securities are owned by Palmetto Partners, Ltd., who is a member of a group with Palmetto Partners 2014, LP and Palmetto Partners 2015, LP.
  • [F4]Each share of preferred stock is convertible on a 1.78112-for-1 basis into Common Stock at any time at the election of the Reporting Persons and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.
  • [F5]As of the date of this Report, the Stock Option is fully vested.

Documents

4 files